New data for Gazyvaro demonstrate leukaemia patients can live 3 years longer without treatment vs. standard of care

New data from two different studies unveiled during the 57th ASH annual meeting highlight the efficacy and safety of Gazyvaro for the treatment of patients with previously untreated chronic… Source link